NEWTON,
Mass., May 29, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that the
Company's senior management team will participate at the
Jefferies Global Healthcare Conference in a fireside chat on
Wednesday, June 5, 2024 at
1:00 p.m. ET in New York, NY.
A live webcast of the event, along with accompanying slides, can
be accessed under "Events & Presentations" in the
Investor section of the Company's
website, http://investors.karyopharm.com/events-presentations,
and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company whose dedication to
pioneering novel cancer therapies is fueled by a belief in the
extraordinary strength and courage of patients with cancer. Since
its founding, Karyopharm has been an industry leader in oral
compounds that address nuclear export dysregulation, a fundamental
mechanism of oncogenesis. Karyopharm's lead compound and
first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO®
(selinexor), is approved in the U.S. and marketed by the Company in
three oncology indications. It has also received regulatory
approvals in various indications in a growing number of ex-U.S.
territories and countries, including Europe and
the United Kingdom (as NEXPOVIO®) and China.
Karyopharm has a focused pipeline targeting indications in multiple
high unmet need cancers, including in multiple myeloma, endometrial
cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).
For more information about our people, science and pipeline, please
visit www.karyopharm.com, and follow us on LinkedIn and on X
at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm
Therapeutics Inc. Any other trademarks referred to in this release
are the property of their respective owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-participate-at-the-jefferies-global-healthcare-conference-302158124.html
SOURCE Karyopharm Therapeutics Inc.